Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-malignant neutropenia

E L Sievers1, D C Dale

  • 1Fred Hutchinson Cancer Research Center, Department of Pediatric Oncology, Seattle, WA, USA.

Blood Reviews
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Neutropenia, a low neutrophil count, can stem from reduced production or survival. Recombinant human granulocyte colony-stimulating factor effectively increases neutrophil counts and improves quality of life in severe chronic neutropenia patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whither thejournal?

Journal of general internal medicine·2016
Same author

Authors' reply.

Journal of postgraduate medicine·2014
Same author

Thyroid storm presenting as congestive heart failure and protein-S deficiency-induced biventricular and internal jugular venous thrombii.

Journal of postgraduate medicine·2013
Same author

The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100.

Clinical pharmacology and therapeutics·2005
Same author

The benefits of haematopoietic growth factors in the management of gynaecological oncology.

European journal of gynaecological oncology·2004
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

Area of Science:

  • Hematology
  • Immunology
  • Stem Cell Biology

Background:

  • Neutropenia is characterized by neutrophil deficiency, impacting the immune system's ability to fight infections.
  • Causes include impaired bone marrow production, increased peripheral utilization, or decreased neutrophil survival.
  • Severe chronic neutropenia (SCN) is defined by consistently low neutrophil levels (<0.5 x 10(9)/L) across diverse etiologies.

Purpose of the Study:

  • To elucidate the mechanisms underlying neutropenia.
  • To explore therapeutic strategies for severe chronic neutropenia.
  • To evaluate the efficacy of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in managing SCN.

Main Methods:

  • Review of existing literature on neutropenia pathogenesis.

Related Experiment Videos

  • Analysis of clinical data regarding neutrophil kinetics and survival.
  • Assessment of rhG-CSF treatment outcomes in SCN patients.

    • Main Results:

    • Neutropenia results from an imbalance between neutrophil production and consumption.
    • Acute neutropenia can be triggered by infections, drug reactions, or autoimmune processes.
    • rhG-CSF administration demonstrated a significant increase in neutrophil counts in most SCN patients.

    Conclusions:

    • Neutropenia encompasses a range of disorders with varied causes.
    • rhG-CSF is a valuable therapeutic agent for severe chronic neutropenia.
    • Treatment with rhG-CSF leads to improved neutrophil levels and enhanced quality of life in SCN patients.